Tests scar-guided heart ablation for persistent atrial fibrillation
Tests extra heart-scar-guided ablation added to standard ablation in adults with persistent atrial fibrillation.
Plain-language title generated from the registry record
Registry title: SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT05794386
- Record updated
- 28 April 2026
- Original description
This is a multicenter, randomized controlled trial to compare the recurrence of 1-year atrial arrhythmia after catheter ablation of atrial fibrillation (AF) between pulmonary vein isolation (PVI) and PVI with additional left atrial (LA) substrate modification based on the left atrial low-voltage area (LA LVA) in patients with persistent AF who had a moderate burden of LVA in LA (1cm2 to <30%).Read full original descriptionShow less
SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation (SCARLET-AF Study)
This is a multicenter, randomized controlled trial to compare the recurrence of 1-year atrial arrhythmia after catheter ablation of atrial fibrillation (AF) between pulmonary vein isolation (PVI) and PVI with additional left atrial (LA) substrate modification based on the left atrial low-voltage area (LA LVA) in patients with persistent AF who had a moderate burden of LVA in LA (1cm2 to <30%).
Inclusion: Patients with symptomatic persistent AF who undergo AF catheter ablation due to continued AF even after anti-arrhythmic agents or; Patients with a burden of LA LVA (scar zone) of 1cm2 or more and less than 30% in 3D voltage mapping before the index catheter ablation are included in the randomized assignment group when performing catheter ablation in satisfaction with 1); Patients with an LVA of <1cm2 or ≥30% are recruited as a registry.
Exclusion: Patients with prior AF-related catheter ablation or surgery; Patients with prior cardiac surgery; Patients with severe structural heart disease (severe mitral regurgitation, hypertrophy cardiomyopathy, other severe valvular heart diseases); Patients who had a myocardial infarction or underwent percutaneous coronary intervention within three months; Patients who had a stroke or transient ischemic attack within 6 months; Patients with intractable hypertension or uncontrolled thyroid disease; Patients who need dialysis due to end-stage renal disease or who are scheduled for dialysis; Patients who are taking immunosuppressive drugs or had undergone chemotherapy for cancer, autoimmune disease, transplant, etc; Known severe left ventricular systolic dysfunction (ejection fraction <35%); Patients with LA anteroposterior diameter of more than 55 mm; Patients whose exact LVA burden cannot be calculated because high-quality 3D voltage mapping cannot be obtained during the procedure; Inability or unwillingness to receive anticoagulation (heparin or oral anticoagulation); Patients with intracardiac thrombus; Patients who had a planned operation or procedure for the cardiovascular system; Patients who are currently pregnant or are likely to be pregnant within the study period; Patients whose life expectancy is less than 1 year.
Ages eligible for the study: 19 years or older.